9939 — Kintor Pharmaceutical Balance Sheet
0.000.00%
- HK$514.62m
- HK$499.28m
- CNY5.00m
Annual balance sheet for Kintor Pharmaceutical, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | IFRS | IFRS | IFRS | IFRS | — |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 1,389 | 1,055 | 875 | 456 | 147 |
Net Total Receivables | 0.555 | 0.692 | 1.93 | 8.66 | 21.7 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 1,421 | 1,526 | 1,508 | 473 | 172 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 187 | 267 | 285 | 222 | 174 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 1,851 | 2,068 | 2,055 | 869 | 515 |
Accounts Payable | |||||
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 169 | 220 | 318 | 225 | 167 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Liabilities | 344 | 413 | 560 | 411 | 221 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
ESOP Debt Guarantee | |||||
Total Equity | 1,508 | 1,655 | 1,495 | 458 | 294 |
Total Liabilities & Shareholders' Equity | 1,851 | 2,068 | 2,055 | 869 | 515 |
Total Common Shares Outstanding |